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Abstract
The effects of exendin-4 on Sirt1 expression as a mechanism of reducing fatty liver have not been previously reported.
Therefore, we investigated whether the beneficial effects of exendin-4 treatment on fatty liver are mediated via Sirt1 in
high-fat (HF) diet-induced obese C57BL/6J mice and related cell culture models. Exendin-4 treatment decreased body
weight, serum free fatty acid (FA), and triglyceride levels in HF-induced obese C57BL/6J mice. Histological analysis showed
that exendin-4 reversed HF-induced hepatic accumulation of lipids and inflammation. Exendin-4 treatment increased mRNA
and protein expression of Sirt1 and its downstream factor, AMPK, in vivo and also induced genes associated with FA
oxidation and glucose metabolism. In addition, a significant increase in the hepatic expression of Lkb1 and Nampt mRNA
was observed in exendin-4-treated groups. We also observed increased expression of phospho-Foxo1 and GLUT2, which are
involved in hepatic glucose metabolism. In HepG2 and Huh7 cells, mRNA and protein expressions of GLP-1R were increased
by exendin-4 treatment in a dose-dependent manner. Exendin-4 enhanced protein expression of Sirt1 and phospho-AMPKa
in HepG2 cells treated with 0.4 mM palmitic acid. We also found that Sirt1 was an upstream regulator of AMPK in
hepatocytes. A novel finding of this study was the observation that expression of GLP-1R is proportional to exendin-4
concentration and exendin-4 could attenuate fatty liver through activation of Sirt1.
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Introduction
Insulin resistance is an important mechanism underlying type 2
diabetes mellitus (T2DM), and recently, non-alcoholic fatty liver
disease (NAFLD) has been reported to be associated with
metabolic diseases such as T2DM, obesity, hypertension, and
insulin resistance [1]. In clinical studies, it has been shown that
weight loss can improve fatty liver, and that reduced liver fat
content confers lower serum fasting insulin and triglyceride (TG)
concentrations compared to subjects with high levels of liver fat
[2]. Thus, fat accumulation in the liver is an important factor for
the development of insulin resistance and dyslipidemia.
Glucagon-like peptide (GLP)-1, an incretin secreted by L-cells in
the small intestine in response to food intake, is known to improve
insulin secretion and its effects on reduction of appetite and body
weight have been demonstrated in both rat [3] and human studies
[4]. Thus, the administration of GLP-1 has been proposed as a
therapeutic approach for T2DM. However, the half-life of
exogenously administered bioactive GLP-1 is less than 2 minutes
in rodents and humans due to its rapid inactivation by circulating
dipeptidyl peptidase-IV (DPP-IV) [5].
Exenatide (exendin-4, Ex-4), a GLP-1 receptor (GLP-1R)
agonist, shares 53% sequence homology with native GLP-1.
Exendin-4 is resistant to DPP-IV mediated degradation, and
therefore has a longer half-life than GLP-1 [6,7]. Recent studies
have shown that GLP-1R is present in human hepatocytes [8] and
that administration of exendin-4 improves insulin resistance in ob/
ob mice and reduces hepatic lipid storage [9]. In addition,
exenatide therapy decreases fasting plasma glucose, body weight,
and liver fat in patients with T2DM [10].
Silent mating type information regulation 2 homolog (sirtuin,
SIRT) 1, one of the seven sirtuins identified in mammalian cells, is
a NAD
+-dependent histone/protein deacetylase that is activated in
response to fasting and caloric restriction (CR). Resveratrol and
SRT1720, both of which are Sirt1 activators, ameliorate fatty liver
with reduced lipid synthesis and increased rates of fatty acid
oxidation through Sirt1 and adenosine monophosphate-activated
protein kinase (AMPK) activation [11]. In addition, activation of
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resveratrol inhibits the expression of SREBP-1 in a cell model of
steatosis induced by palmitate [12].
However, the effects of exendin-4 treatment on Sirt1 expression
in a fatty liver model have not been previously reported.
Therefore, we investigated whether the beneficial effects of
exendin-4 treatment on fatty liver could be mediated via Sirt1 in
high-fat (HF) diet-induced obese C57BL/6J mice and related cell
culture models.
Materials and Methods
Animals
Six-week-old C57BL/6J mice were obtained from Central
Laboratory (Shizuoka Laboratory Animal Center, Shizuoka,
Japan) and bred under standard conditions with a 12-h light/
dark cycle. All procedures were approved by the Ethics
Committee for Animal Experiments of the Sungkyunkwan
University Kangbuk Samsung Hospital (Approval ID:
201103022). Mice were randomly divided into 3 groups (n=10/
group) as follows: low-fat diet (control, 10 kcal % fat, 20 kcal %
protein, and 70 kcal % carbohydrate); HF diet (HF, 45 kcal % fat,
20 kcal % protein, and 35 kcal % carbohydrate); and HF diet plus
1 nmol/kg/day exendin-4 (Sigma-Aldrich Corp., St. Louis, MO,
USA) via intraperitoneal (IP) injection. For the former diet
regimen, exendin-4 was injected every other day while saline was
injected to the other groups every other day for 10 weeks. The
mice were allowed access to their specific diet and water ad libitum.
In all experiments, body weight and food intake were checked
twice per week. In the 11
th week, after overnight fasting, the
animals were sacrificed, and liver tissues were extracted,
immediately frozen in liquid nitrogen, and stored at 280uC until
RNA and protein extraction.
Cell culture
HepG2 and Huh7 human hepatoma cell lines were purchased
from American Type Culture Collection (ATCC, Manassas, VA,
USA) and Korean Cell Line Bank (KCLB, Seoul, Korea),
respectively, and cultured in 6-well plates in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco, Grand Island, NY, USA)
containing 10% fetal bovine serum (Gibco), 1% penicillin/
streptomycin (Gibco) [8]. At 70–80% confluence, cells were
pretreated with or without nicotinamide (10 mM) (Fluka AG,
Buchs SG, Switzerland), an inhibitor of SIRT1, or Compound C
(10 mM) (Calbiochem, La Jolla, Calif, CA, USA), an inhibitor of
AMPK, in serum-free DMEM for 24 h. Afterwards, exendin-4 (50
or 100 nM) (Sigma-Aldrich Corp.) was added to the wells in
0.4 mM palmitic acid (Sigma-Aldrich Corp.), prepared as
described previously [13].
Oil red O staining
HepG2 and Huh7 cells were plated in chamber slides. Briefly,
cells were washed 3 times with PBS, fixed for 30 minutes with 4%
paraformaldehyde in PBS, stained with Oil-Red O for 1 hour, and
then rinsed with distilled water. Finally, the cells were examined by
light microscopy (magnification, 6400). For quantitative analysis
of lipid accumulation, 1 mL isopropanol was added to the stained
culture plate and the absorbance was recorded at 540 nm.
Serum analysis
After overnight fasting, serum samples were obtained for analysis
of free fatty acid (FFA) and triglyceride (TG). Serum samples were
separated by centrifugation at 4uC and stored at 280uC until
measurements were performed. Plasma concentrations were
measured usingan enzyme-based FFAquantificationkit(BioVision,
Mountain View, CA, USA) and a TG assay kit (Cayman Chemical,
Ann Arbor, MI, USA).
Total RNA extraction and real-time RT-PCR
Total RNA was extracted from liver tissue using Trizol reagent
(Invitrogen, Carlsbad, CA, USA). Generation of cDNA was
performed by reverse transcribing 2 mg of total RNA with
moloney murine leukemia virus reverse transcriptase (MMLV-
RT) and oligo (dT)12–18 primer (Invitrogen). Briefly, RNA was
denatured for 10 minutes at 72uC, then immediately placed on ice
for 5 minutes. Denatured RNA added to a mixture of MMLV-
RT, MMLV-RT buffer, and dNTPs and incubated for 1 h at
42uC. Then, reagent was inactivated by heating at 95uC for
2 minutes. Synthesized cDNA was amplified by real-time PCR
(Light-Cycler 480; Roche, Lewis, UK) using SYBR green
(Invitrogen) and specific primers (Bioneer Co., Daejon, Korea).
Each cycle consisted of denaturation at 94uC for 15 seconds,
annealing at 55uC for 10 seconds, and extension at 72uC for
20 seconds. Quantification was performed using the comparative
2-(delta delta Ct) method, i.e., expression levels for the target genes
were normalized to the b-actin (Actb) of each sample.
Western blot analysis
For western blot analysis, liver (100 mg wet weight) was
homogenized at 4uC in 300 ml of RIPA buffer (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA). After a 30 minute-
incubation on ice, protein was obtained by centrifugation at
12,000 rpm for 20 minutes at 4uC. Extraction of nuclear proteins
was performed using nuclear extraction kit (Cayman Chemical
Co., Ann Arbor, MI). The samples containing 30 mg of protein
were separated on 4%–12% bis-Tris Nupage gels (Invitrogen) and
transferred to polyvinylidene difluoride membranes. After transfer,
the membranes were incubated overnight at 4uC with antibodies
against GLP-1R (H-55, sc-66911; Santa Cruz Biotechnology,
Inc.), SIRT1 (H-300, sc-15404; Santa Cruz Biotechnology, Inc.),
phospho-AMPKa (Thr172, #2531; Cell Signaling Technology,
Danvers, MA, USA), phosphor-FOXO1 (pS
249, 441245G;
Invitrogen), glucose transporter 2 (GLUT2, H-67, sc-9117; Santa
Cruz Biotechnology, Inc.), and b-actin (#4967; Cell Signaling
Technology). Membranes were incubated with horseradish
peroxidase conjugated secondary antibodies, and visualized using
enhanced chemiluminescence western blotting detection reagents.
Histological analysis
After anesthesia, liver tissues were removed from animals and
fixed in 10% neutral buffered formalin and embedded in paraffin.
Then, the paraffin blocks were cut on a microtome into 5 mm thick
sections. After deparaffinization and dehydration, 5-mm thick
sections were stained with hematoxylin (catalog no. GHS132;
Sigma-Aldrich Corp.) and eosin (H&E, catalog no. HT110116;
Sigma-Aldrich Corp.). Histological slides were examined by light
microscopy (magnification, 6200). Histological features including
steatosis, inflammation, and hepatocellular injury were histolog-
ically graded by two pathologists [14]. Hepatic triglycerides were
extracted from frozen tissue and measured by enzymatic assays
(Sigma). Values of TG were normalized to protein concentration.
Statistical analysis
Data and results were reported as means 6 SE. Statistical
comparisons were performed with paired two-tailed t-tests. Values
of P,0.05 were considered statistically significant unless otherwise
indicated.
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Effects of exendin-4 treatment on body weight, food
intake, and serum FFA and TG levels
The final body weight of the HF group was higher than that of
the control group (45.260.72 g vs. 29.760.5 g in the control
group) and that of the exendin-4-treated group (4160.9 g) was
significantly decreased compared with the HF group (Fig. 1A).
However, despite the increase in body weight by HF, the food
intake of HF group (3.2760.19 g) was significantly decreased
compared with the control group (4.460.22 g). There were no
differences in food intake between the exendin-4-treated group
(3.1860.18 g) and the HF group (Fig. 1B). Exendin-4 treatment
decreased the serum FFA level by 1.3-fold compared with the HF
group (Fig. 1C). In addition, the TG level in the exendin-4-treated
group was also decreased 1.3-fold compared with the HF group
(Fig. 1D). The lowest levels of serum FFA and TG were noted in
the control group.
Exendin-4 treatment increases the hepatic expressions of
GLP-1R, Nampt, Sirt1, Lkb1, and AMPKa
The effect of exendin-4 treatment, as a GLP-1R agonist, on the
level of expression of GLP-1R was measured by western blot assay.
Expression of GLP-1R in the HF group was decreased compared
to that of the control group while exendin-4 treatment increased
the expression of GLP-1R in liver tissue of mice compared with
the HF group (Fig. 2B). In addition, the effect of exendin-4
treatment on mRNA and protein expression of hepatic Sirt1,
Lkb1, and AMPKa was measured by real-time PCR and western
blot assay. As shown in Fig. 2, mRNA expression of Sirt1, Lkb1,
AMPKa1, and AMPKa2, as well as protein expression of Sirt1 and
phospho-AMPKa, were significantly decreased in the HF group
compared with the control group and were reversed by exendin-4
treatment. Recently, Revollo et al. [15] reported nicotinamide
phosphoribosyltransferase (Nampt), functioning as a systemic
NAD biosynthetic enzyme, regulates Sirt1 activity in mammalian
cells. Therefore, we examined whether exendin-4 could affect the
Figure 1. Change of body weight, food intake, and serum lipid levels by exendin-4 in HF-induced obese mice. Mice divided into 3
groups were fed low fat diet, high fat diet, or high fat diet with 1 nmol/kg/day exendin-4 ip injection for 10 weeks. (A) Body weight and (B) food
intake was checked twice per week. (C–D) When sacrificed at 11 weeks, serum samples were obtained for analysis of free fatty acid (FFA) and
triglyceride (TG) after overnight starvation. All values are expressed as the mean 6 SE for n=8 mice. * p,0.05, ** p,0.01 compared with a control
and # p,0.05, ## p,0.01 compared with a HF.
doi:10.1371/journal.pone.0031394.g001
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expression level was significantly decreased compared with the
control group while exendin-4 treatment significantly increased
the expression of Nampt mRNA compared with its expression in
the HF group (Fig. 2A).
Effect of exendin-4 treatment on the hepatic expressions
of genes associated with fatty acid oxidation, lipogenesis,
and glucose homeostasis
The level of hepatic expression of fatty acid oxidation and
lipogenesis-associated genes by exendin-4 treatment was assessed
using real-time PCR (Figs. 3A–B). The expressions of adiponectin
(Adipoq) and adiponectin receptor 2 (Adipor2) mRNA were
decreased in the HF group compared with the control group
and increased in the exendin-4- treated group compared with the
HF group. A homologous gene of Adipor2, adiponectin receptor 1
(Adipor1), was also decreased in the HF group compared with the
control group. However, no significant difference in the level of
expression level of the Adipor1 was observed between in the HF
and exendin-4-treated groups. The HF group also exhibited a
decrease in the expression of genes that are known to be regulated
by peroxisome proliferator-activated receptor- a (Ppara), such as
acyl-CoA oxidase (Acox) and medium chain acyl-coenzyme A
dehydrogenase (MCAD) enzymes, which catalyze the key steps in
peroxisomal and mitochondrial b-oxidation, respectively. On the
other hand, the expressions of these genes were increased in the
exendin-4-treated group compared with the HF group (Fig. 3A).
As shown in Fig. 3B, sterol regulatory element binding protein-1c
(SREBP-1c) and stearoyl CoA desaturase-1 (Scd-1) mRNA, which
are key regulators of the de novo hepatic lipogenesis pathway, were
decreased by exendin-4 treatment in HF- induced obese C57BL/
6J mice. However, no significant difference was observed between
the control and HF groups in the level of expression level of
SREBP-1c mRNA. In addition, we observed changes in the
expression of fatty acid synthase (Fasn) and acetyl-coenzyme A
carboxylase alpha (Acaca) mRNA, which encode for lipogenic
enzymes that are mediated by SREBP-1c. Fasn was decreased in
the HF group compared with the control group and increased in
the exendin-4-treated group compared with the HF group, but
detected no change between the control and the exendin-4-treated
group. Whereas, no significant difference in the level of expression
level of the Acaca was observed between all groups. Therefore,
these data suggest that the beneficial effects of exendin-4 on lipid
metabolism are controlled through the regulation of fatty acid-
oxidation rather than lipogenesis. Moreover, HF-decreased
protein expression of phospho-Foxo1 and GLUT2, which are
involved in hepatic glucose metabolism, was increased by exendin-
4 treatment (Fig. 3C).
Effect of exendin-4 treatment on liver fat accumulation
As shown in Fig. 4A–C, hepatic accumulation of lipids was
significantly higher in the HF group compared with the control
group and was decreased by exendin-4 treatment. In addition,
mean scores for steatosis, ballooning and lobular inflammation
based on H&E staining were significantly decreased in the
exendin-4-treated group compared with the HF group (Fig. 4D).
In the HF group, hepatic TG levels were dramatically increased
compared with the control group, whereas it was decreased in the
exendin-4 -treated group (Fig. 4E).
Effect of exendin-4 treatment on PA-induced hepatic
lipid accumulation in vitro
Lipid accumulation in HepG2 and Huh7 cells was examined by
Oil-red O staining. Cells treated with PA, a saturated fatty acid,
for 24 h had increased cellular lipid accumulation (Fig. 5). As
shown by the photomicrographs, the significant changes of lipid
droplets indicated that PA induced an increase of intracellular
lipid content, and that exendin-4 could decrease PA-increased
Figure 2. Change of Sirt1 and AMPK pathway and GLP-1R expression by exendin-4 in mouse livers. Total RNA and protein were
extracted from liver tissue and (A) Nampt, Sirt1, Lkb1, AMPKa1 and AMPKa1 mRNA and (B) GLP-1R, Sirt1, phospho-AMPKa, AMPK and b-actin protein
expression were measured by quantitative real-time RT-PCR and western blot, respectively. Data were normalized to the b-actin of each sample. All
values are expressed as the mean 6 SE for n=5–7 mice. * p,0.05, ** p,0.01 compared with a control and # p,0.05, ## p,0.01 compared with a
HF.
doi:10.1371/journal.pone.0031394.g002
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spectrophotometer at 540 nm was consistent with visual staining
analysis (Fig. 5B).
Effects of exendin-4 treatment on regulation of GLP-1R,
Sirt1 and AMPK in vitro
To investigate whether the actions of exendin-4 are mediated by
GLP-1R, HepG2 and Huh7 cells were treated with different doses
of exendin-4. The expression of GLP-1R mRNA and protein was
increased by 100 nM and 500 nM exendin-4 treatment, whereas
it was decreased in cells treated with 50 nM exendin-4 compared
with control cells (Fig. 6A).
Increased levels of Sirt1 and AMPK expression by exendin-4
were observed not only in vivo, but also in vitro. Exendin-4 (100 nM)
treatment enhanced the protein expression of Sirt1 and phospho-
AMPK in HepG2 cells treated with 0.4 mM palmitic acid
Figure 3. Effect of exendin-4 on expression of genes associated with fatty acid oxidation, lipogenesis, and glucose homeostasis. (A)
Adiponectin (Adipoq), adiponectin receptor 1 (AdipoR1), adiponectin receptor 1 (AdipoR2), peroxisome proliferator-activated receptor- a (Ppara), acyl-
CoA oxidase (Acox), and medium chain acyl-Coenzyme A dehydrogenase (MCAD); (B) sterol regulatory element binding protein 1c (SREBP-1c),
stearoyl-Coenzyme A desaturase 1 (Scd-1), fatty acid synthase (Fasn), and acetyl-Coenzyme A carboxylase alpha (Acaca) mRNA expression; and (C)
GLUT2, phosphorylated Foxo1 at serine 349, Foxo1 and b-actin protein expression in mouse livers were measured by quantitative real-time RT-PCR
and western blot and were normalized to the b-actin of each sample. All values are expressed as the mean 6 SE for n=5–7 mice. * P,0.05, ** P,0.01
compared with a control and # p,0.05, ## p,0.01 compared with a HF.
doi:10.1371/journal.pone.0031394.g003
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AMPKa was observed in cells treated with 50 nM exendin-4,
consistent with the results shown in Fig. 6A. Therefore, we decided
to use a concentration of 100 -nM exendin-4 in further
experiments.
Furthermore, to investigate whether AMPK is regulated by
Sirt1, exendin-4 was added to HepG2 cells pretreated with or
without either nicotinamide, a Sirt1 inhibitor, or Compound C, an
AMPK inhibitor. As expected, in cells treated with PA, expression
levels of Sirt1 and AMPK were decreased compared with cells
treated with control and exendin-4. Also, nicotinamide signifi-
cantly repressed Sirt1 and AMPKa expression compared with
exendin-4 alone, whereas decreased Sirt1 expression by inhibition
of AMPK in Compound C treatment was not observed. These
data suggest that Sirt1 is an upstream regulator of AMPK in
hepatocytes (Fig. 6C).
Discussion
In this study, exendin-4 treatment resulted in a reduction of
body weight and improvement in fat accumulation in liver tissues
of a HF-induced obese mouse model. Together, we demonstrated
that exendin-4 administration affected hepatic lipid metabolism
via the Sirt1 signaling cascade, which are involved in fatty acid
oxidation and lipid and glucose metabolism. However, interest-
ingly the effects of exendin-4 treatment on appetite failed to
coincide with those of previous studies, which reported a reduction
in both body weight and appetite by exendin-4 administration
[16]. This finding, that exendin-4 limited HF-induced weight gain
despite no change in food intake (figure 1), is thought to be due to
markedly increased energy expenditure, which was correlated with
increased fatty acid oxidation. Recent studies showed that weight
loss could decrease hepatic steatosis and insulin sensitivity [17] and
Figure 4. Histopathology of mice fed control (low fat), HF, HF+exendin-4 diet for 10 wks. Sections were stained with H&E. Arrows
indicates lipid droplets. (A–C) Liver sections of mice fed control, HF and HF+Ex-4, respectively. (magnification,6200). Scale bars=500 mm. (D) NAFLD
activity scores were evaluated semi-quantitatively: steatosis (0–3), lobular inflammation (0–2), and hepatocellular ballooning (0–2). N.D., not detected
(E) Hepatic triglycerides were extracted from frozen tissue and measured by enzymatic assays. Values of TG were normalized to protein
concentration. * p,0.05, ** p,0.01 compared with a control and # p,0.05, ## p,0.01 compared with a HF.
doi:10.1371/journal.pone.0031394.g004
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NASH could be mediated by activating of genes involved in fatty
acid oxidation and insulin sensitivity [18]. In other words, it
suggests that the effect of exendin-4 on liver is associated with
weight loss.
GLP-1R is known to be widely expressed in pancreatic islets,
lung, brain, heart, kidney, and stomach, and recently reported
studies have focused mainly on the role of exendin-4 treatment in
pancreatic islets. In addition, recent studies have demonstrated
that GLP-1R is also present in human and rat hepatocytes [8,9],
and hepatic GLP-1 R expression is decreased in human subjects
with NASH [18]. Furthermore, our results revealed that HF
treatment decreased expression of GLP-1R in mouse hepatocytes,
and that the expression of GLP-1R was increased by exendin-4
treatment in a dose-dependent manner in human hepatocytes,
suggesting that GLP-1 might act directly on liver signaling.
Sirt1 and AMPK are signaling molecules that control hepatic
lipid metabolism by deacetylation of acetylated lysine residues on
histones and various transcriptional regulators, depending on
intracellular NAD
+/NAD ratios and phosphorylation via an
increase in the AMP/ATP ratio, respectively [19,20]. In the
present study, we showed that Nampt expression was induced by
exendin-4 treatment. The Nampt/visfatin enzyme catalyzes the
reconversion of NAM to NAD
+ and is required for Sirt1 activity
[15]. Therefore, it is suggested that exendin-4 treatment increases
Sirt1 expression via the NAD biosynthesis pathway.
Recently, an association was demonstrated between Sirt1 and
AMPK signaling. Specifically, Sirt1 was found to regulate AMPK
Figure 5. Effect of exendin-4 on PA-induced lipid accumulation in human hepatocytes. HepG2 and Huh7cells were treated with PA
(0.4 mM) with or without Ex-4 (100 nM) for 24 h and lipid accumulation in cells was observed by Oil-red O staining. (A) HepG2 and Huh7 cells stained
with Oil-red O were examined by light microscopy (magnification, 6400). Cells treated with 10% BSA, 0.4 mM PA and 0.4 mM PA+100 nM Ex-4; (B)
intracellular lipid droplets were quantified using a spectrophotometer at 540 nm. * p,0.05, ** p,0.01 compared with a control and # p,0.05, ##
p,0.01 compared with PA. Scale bars=100 mm.
doi:10.1371/journal.pone.0031394.g005
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AMPK in hepatic cells in animal models [21–23]. On the other
hand, AMPK enhances SIRT1 activity by increasing cellular
NAD+ levels in mouse skeletal muscle [24]. Evidence for a Sirt1/
AMPK signaling mechanism by exendin-4 treatment was observed
in this study. In our in vitro study, the Sirt1 inhibitor nicotinamide
decreased AMPKa expression, whereas a decrease in Sirt1
expression by an AMPK inhibitor, compound C, was not
observed. These results indicate that Sirt1 is an upstream factor
of AMPK, at least in hepatocytes.
AMPK activated by phosphorylation plays an important role
via phosphorylation of its downstream genes in b-oxidation of fatty
acid and glucose uptake [25]. Fatty acid oxidation in liver by 5-
aminoimidazole-4-carboxamide ribonucleoside (AICAR) and met-
formin administration, an oral hypoglycemic agent, are also
mediated by the activation of AMPK [26,27]. In our study, HF
significantly decreased the expression of genes associated with fatty
acid oxidation, including the Adipoq and Ppara target genes, such as
MACD and Acox, which are key enzymes involved in mitochondrial
and peroxisomal b-oxidation, respectively. Adiponectin, as the key
regulator of fatty acid oxidation in skeletal muscle and liver,
increases AMPK and PPARa ligand activities. At this time,
adiponectin-mediated modulation of AMPK depends on LKB
[25,26]. These actions of adiponectin are mediated by Adipor1
and Adipor2, which serve as receptors for globular and full-length
adiponectin. Indeed, it has been reported that Adipor1 and
Adipor2 are abundantly expressed in skeletal muscle and liver,
respectively [28]. In our experiments, expression of Adipor2 was
increased in the exendin-4-treated group compared with HF
group, whereas no change in expression of Adipor1 was observed
between the exendin-4-treated group and HF group. Thus, this
result suggests that the antidiabetic effects of exendin-4-increased
adiponectin are mediated by Adipor2. Further, these results may
clarify whether one of the hepatic functions of exendin-4 treatment
is through modulation of the fatty acid oxidation-associated signal
transduction pathway.
In this study, histological images of HF mice showed a
significant increase of lipid droplets in liver tissues. Further,
exendin-4 treatment inhibited the development of NAFLD in HF-
induced hepatic steatosis and plasma TG levels in HF-induced
obese C57BL/6J mice. A previous study reported that exendin-4
impairs hepatocyte de novo lipogenesis by decreasing mRNA
expression for SCD-1, SREBP-1c, and ACC in ob/ob mice [9]. For
this reason, we expected that extendin-4 would regulate not only
fatty acid oxidation, but also lipid metabolism, for the treatment of
NAFLD. However, Fasn, which is lipogenic enzyme mediated by
SREBP-1c, was decreased in the HF group, and change of Acaca
was not observed between all groups. Higher level of lipogenic
enzyme in the control group than the HF group can be explained
by the difference in carbohydrate contents of the respective diets,
due to the fact that dietary carbohydrate are transformed to fat via
de novo lipogenesis processes.
In addition, conflicting results between previous studies and the
present study with respect to expression of lipogenesis-associated
genes may be due to the use of different mouse models, namely
genetically and diet-induced obese mice. The results presented
here showing that the effects of exendin-4 for improvement of
hepatic steatosis give weight to a stimulatory role of exendin-4 on
fatty acid oxidation rather than lipogenesis. In this study, animals
were studied in the fasted state. Thus, it can be difficult to
conclude about the changes in gene expression observed for genes
encoding enzymes involved in lipogenesis. It could be better to
perform experiments in feeding state.
The prevalence of NAFLD is associated with impaired glucose
metabolism [29], whereby control of hepatic gluconeogenesis and
glucose uptake is essential for maintenance of normal blood
glucose concentrations. In this study, HF reduced hepatic phopho-
Foxo1 and GLUT2 expression. FOXO1 and TORC2, which
have been reported to promote gluconeogenesis, are repressed by
SIRT1, resulting in decreased hepatic glucose production and
improved glucose tolerance [30,31]. In agreement with our data,
exendin-4 improves glucose metabolism by enhancing hepatic
insulin signaling and glucose uptake in the diabetic state [8,32,33]
Although exenatide does not function as a direct insulin
sensitizer, there are reports on the positive effects of GLP-1 on
NAFLD in human [10,34]. A clinical trial using exenatide to assess
drug safety in diabetics over an average period of 3.5 years
revealed that patients with liver injury as assessed by elevated liver
enzymes at baseline showed significant improvement in liver
enzymes [34]. However, these effects were not reported to be
associated with weight reduction. Another case report noted
significant improvement in hepatic steatosis measured by liver
spectroscopy after 44 weeks of treatment with exenatide [10].
Although the results from animal studies cannot be directly
applied to humans due to the genetic differences across the species,
the effects of exenatide on hepatic steatosis in humans is one of the
interesting and promising aspects of incretin that has to be clarified
through well-designed clinical trials in humans.
In summary, this study reveals that expression of hepatic GLP-
1R is decreased by HF administration in mice, whereas it is
directly proportional to exendin-4 concentration in human
hepatocytes. In HF-treated mice, exendin-4 treatment ameliorated
inflammation and steatosis, and increased sirt1 by exendin-4 lead
to activation of AMPK and its downstream target genes, involving
fatty acid oxidation. Therefore, the present study suggests that
exendin-4 treatment may attenuate fat accumulation and improve
glucose metabolism in liver tissues through the activation of Sirt1
signaling cascade, and further may serve as a therapeutic agent for
fatty liver disease associated with metabolic diseases, such as
obesity and T2DM.
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Figure 6. Regulation of GLP-1R, Sirt1 and AMPK by exendin-4 in HepG2 and Huh7 cells. (A) Cells were treated with 50 nM, 100 nM, or
500 nM Ex-4 for 24 h. GLP-1R and b-actin were measured by western blot and real time PCR. GLP-1R was normalized to b-actin. (B) Cells given 0.4 mM
palmitic acid (PA) were treated with either vehicle or 50 nM to 100 nM exendin-4 for 24 h. (C) Cells given 0.4 mM palmitic acid were treated with
100 nM exendin-4 in the absence or presence of 10 mM nicotinamice (NAM) or 10 uM compound C (CC) for 24 h. (B–C) Sirt1, phosphorylated AMPKa
at threonine 172, AMPK and b-actin were measured by western blot in HepG2 cells. Sirt1 and phosphorylated AMPKa were normalized to the b-actin
and total AMPK of each sample, respectively. * p,0.05, ** p,0.01 compared with control, # p,0.05, ## p,0.01 compared with PA, and { p,0.05,
{{ p,0.01 compared with Ex-4.
doi:10.1371/journal.pone.0031394.g006
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